Drug intelligence / Profile preview

SUN-131

Development stage: Phase 3
Lead developer: Senju Pharmaceutical
Modality: Small Molecules
Administration: Transdermal, Ophthalmic

Overview

SUN-131 is a transdermal patch (TDS - Transdermal System) being developed by Senju Pharmaceutical through its subsidiary Senju USA for the treatment of chalazion. It is designed for local delivery of a corticosteroid to the upper or lower eyelid. The drug acts as a steroid receptor agonist and belongs to the anti-inflammatory and corticosteroid class of medications.

Other names: triamcinolone acetonide transdermal systemtriamcinolone acetonide patch

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on SUN-131.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SUN-131.

Explore the full profile